Tasimelteon

證據等級: L5

預測適應症: 10 個

Tasimelteon: From Non-24-Hour Sleep-Wake Disorder to Insomnia

One-Sentence Summary

Tasimelteon is a melatonin MT1/MT2 receptor agonist currently approved for Non-24-Hour Sleep-Wake Disorder, acting on the suprachiasmatic nucleus to regulate circadian rhythm and sleep onset. The TxGNN model predicts it may also be effective for Insomnia, with 4 clinical trials (including one completed Phase 3 RCT) and 6 supporting publications currently identified. Note: TxGNN generated 9 other candidate indications for tasimelteon (e.g., ALS, polymicrogyria, endogenous depression), but all except insomnia lack meaningful clinical or literature support and are rated Hold (L5) or Research Question (L4) — this report focuses on the insomnia candidate, which has by far the strongest evidence.

Quick Overview

Item	Content
Original Indication	Non-24-Hour Sleep-Wake Disorder (existing approved indication, referenced in evidence rationale)
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.47%
Evidence Level	L1
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available (flagged as a High-severity data gap, DG002). However, the evidence pack's repurposing rationale confirms that tasimelteon is a melatonin MT1/MT2 receptor agonist, acting directly on the suprachiasmatic nucleus (SCN) — the body's circadian pacemaker — to regulate circadian rhythm and promote sleep initiation.

Insomnia and Non-24-Hour Sleep-Wake Disorder are both circadian-rhythm-related sleep disorders sharing the same underlying pathophysiology: dysregulation of the sleep-wake cycle. Since tasimelteon's approved indication already targets this pathway, its predicted efficacy in insomnia represents a mechanistically coherent extension within the same therapeutic class, rather than a novel unrelated use. This is consistent with the broader melatonergic drug class (ramelteon, agomelatine), which is also used across both circadian rhythm disorders and primary insomnia.

It is worth noting this significant overlap means the "repurposing" value here may be incremental rather than transformative, since the mechanistic rationale for insomnia is essentially an extension of the drug's existing chronobiotic action rather than a discovery of a novel therapeutic pathway.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00548340	Phase 3	Completed	322	Multicenter, double-blind, placebo-controlled 5-week trial of VEC-162 (tasimelteon) 20mg/50mg in primary insomnia; highest-quality evidence to date.
NCT06953869	Phase 3	Recruiting	420	Multicenter, double-blind, randomized study evaluating tasimelteon vs. placebo in pediatric insomnia disorder.
NCT03291041	Phase 2	Completed	25	Proof-of-concept study of tasimelteon vs. placebo in travelers with jet lag disorder; related but not core primary insomnia population.
NCT05922995	Early Phase 1	Terminated	20	Single-center, open-label pilot study of tasimelteon in REM Behavior Disorder, also assessing insomnia symptom scales (ISI, PSQI); terminated, low evidentiary value.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25207602	2014	Review	Int J Mol Sci	Reviews therapeutic effects of melatonin receptor agonists (including tasimelteon) on sleep and comorbid disorders.
24228714	2014	Review	J Med Chem	Reviews MT1/MT2 receptor pharmacology and therapeutic potential of melatonergic drugs including tasimelteon.
19557144	2009	Review	Neuropsychiatr Dis Treat	Discusses management of insomnia with prolonged-release melatonin and synthetic melatoninergic agonists.
35585820	2023	Review	Curr Drug Saf	Discusses melatonin and tasimelteon in the context of Alzheimer's disease-related insomnia and cognitive decline.
22010042	2011	Review	Ther Adv Neurol Disord	Reviews melatonin analogs' therapeutic potential for sleep disorders in Parkinson's disease.
22167135	2011	Review	Neuro Endocrinol Lett	Discusses circadian sleep disruption and possible therapeutic value of melatonin in obesity-related sleep disorders.

Germany Market Information

No market authorization records are currently registered in Germany — tasimelteon is not marketed (0 authorizations found).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are currently unavailable — flagged as Blocking data gap DG001, requiring TFDA/BfArM label retrieval before safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The insomnia prediction is supported by L1 evidence, including one completed Phase 3 RCT (NCT00548340, n=322) and an ongoing pediatric Phase 3 trial, plus a mechanistically coherent link to tasimelteon's existing approved indication. However, the drug is not currently marketed in Germany, and safety labeling data remains an unresolved blocking gap.

To proceed, the following is needed:

Resolve DG001 (Blocking): Retrieve official TFDA/BfArM product labeling for warnings, contraindications, and DDI data before any S1 safety evaluation.
Resolve DG002 (High): Confirm formal mechanism-of-action documentation via DrugBank API to validate the mechanistic rationale currently derived only from repurposing_rationale text.
Clarify degree of indication overlap with the existing Non-24-Hour Sleep-Wake Disorder approval, to determine whether this constitutes a genuine label extension or requires a distinct regulatory pathway.
Monitor completion of NCT06953869 (pediatric Phase 3, est. completion 2028-01) for confirmatory evidence.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.